This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay D treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
is ushering in a new era of brain disorder treatment. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medicine studies, BrainsWay represents the next-generation of treatments for depression, OCD, and other brain disorders, achieving outcomes not thought possible with traditional medical solutions.
*See response and remission rates in the MDD and OCD treatment pages
Alzheimer’s disease is a major cause of severe cognitive decline in the aged.
Bipolar disorder, also known as manic-depressive illness
A brain stroke is the loss of brain function due to a disturbance in the blood supply to the brain.
Multiple Sclerosis (MSc) is an inflammatory demyelinating condition of the central nervous system
Parkinson’s disease is a degenerative disorder of the central nervous system
Anti-psychotic medications are often effective for the positive symptoms of schizophrenia
Autism is a complex developmental disability that typically appears during the first three years of life
Post-traumatic stress disorder (PTSD) is an extreme anxiety response to a life-threatening situation
Neuropathy is common in the diabetic population, affecting approximately 50% of patients with long-lasting diseases.
Tobacco smoking is the leading cause of preventable death in developed countries.
BrainsWay OCD – a noninvasive, innovative treatment – is transforming the treatment of OCD.
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
OF POPULATION IS COVERED BY REIMBURSEMENT